letrozole has been researched along with Disease Models, Animal in 116 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study aimed to investigate whether time-restricted feeding (TRF) ameliorates metabolic and reproductive phenotypes in a letrozole-induced mouse model of polycystic ovary syndrome (PCOS)." | 8.31 | Effects of time-restricted feeding on letrozole-induced mouse model of polycystic ovary syndrome. ( Han, YI; Jeong, HG; Kim, T; Lee, HJ; Nam, S; Park, H; Ryu, KJ, 2023) |
| "The objective of the present study was to investigate the effect of melatonin and L-thyroxine (T4) on the expression of various receptors, and some metabolic, reproductive, and gonadotropic hormones in letrozole-induced polycystic ovary syndrome (PCOS) in rats." | 8.12 | Differential expression and interaction of melatonin and thyroid hormone receptors with estrogen receptor α improve ovarian functions in letrozole-induced rat polycystic ovary syndrome. ( Brown, GM; Cardinali, DP; Ghosh, H; Manzar, MD; Pandi-Perumal, SR; Rai, S; Reiter, RJ, 2022) |
| " In this regard, studies have demonstrated that Aloe vera gel has the potential to modulate steroidogenic activity in letrozole induced polycystic ovary syndrome (PCOS) rat." | 8.12 | Partially purified non-polar phytocomponents from Aloe barbadensis Mill. gel restores metabolic and reproductive comorbidities in letrozole-induced polycystic ovary syndrome rodent model- an "in-vivo" study. ( Dey, A; Dhadhal, S; Maharjan, R; Nagar, PS; Nampoothiri, L, 2022) |
| "The impact of low-dose spironolactone (LSPL) on polycystic ovarian syndrome (PCOS)-associated cardio-renal disorder is unknown." | 8.12 | Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model. ( Akintayo, CO; Areloegbe, SE; Aturamu, A; Olaniyi, KS; Oniyide, AA; Peter, MU, 2022) |
| " deltoidea at the dose of 500 and 1000 mg/kg/day reduced insulin resistance, obesity indices, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL), malondialdehyde (MDA), testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) to near-normal levels in PCOS rats." | 8.02 | Ficus deltoidea ameliorates biochemical, hormonal, and histomorphometric changes in letrozole-induced polycystic ovarian syndrome rats. ( Goh, YM; Hashim, N; Haslan, MA; Samsulrizal, N; Shirazi, FH; Zin, NSNM, 2021) |
| " Liraglutide has favourable neuroprotective effects that may protect against the possible cognitive dysfunction in PCOS." | 8.02 | Liraglutide mends cognitive impairment by averting Notch signaling pathway overexpression in a rat model of polycystic ovary syndrome. ( Abdel Salam, RM; Ahmed, MAE; Eltarzy, MA; Saad, MA, 2021) |
| "The present study was conducted to investigate the therapeutic effects of a potent polyphenol, fisetin, on the letrozole-induced rat model of polycystic ovary syndrome (PCOS)." | 8.02 | Ameliorative effects of fisetin in letrozole-induced rat model of polycystic ovary syndrome. ( Khadem-Ansari, MH; Mihanfar, A; Nouri, M; Roshangar, L, 2021) |
| "BACKGROUND The aim of this study was to explore whether letrozole and high-fat diets (HFD) can induce obese insulin-resistant polycystic ovary syndrome (PCOS) with all reproductive and metabolic phenotypes in a rat model." | 7.96 | Letrozole Rat Model Mimics Human Polycystic Ovarian Syndrome and Changes in Insulin Signal Pathways. ( Dun, J; Huang, L; Huang, M; Ji, F; Lin, Q; Lin, Y; Xu, J; Yang, J; You, X; Zhang, J, 2020) |
| " The study investigated the effects of quercetin in a letrozole induced rat model of polycystic ovarian syndrome, which displayed both clinical and metabolic features as in PCOS women." | 7.88 | Therapeutic potentials of Quercetin in management of polycystic ovarian syndrome using Letrozole induced rat model: a histological and a biochemical study. ( Abid, A; Afsar, T; Almajwal, A; Jahan, S; Khalid, S; Razak, S; Shaheen, G, 2018) |
| "Soy isoflavones (100 mg/kg) treatment significantly altered the letrozole-induced PCOS symptoms as observed by decreased body weight gain (p < 0." | 7.85 | Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism. ( Balaji, B; M, SS; Rajan, RK, 2017) |
| " Polycystic ovary syndrome was induced by letrozole administration, and animals presented with obesity, sex hormone disorder, no ovulation, large cystic follicles, and increasing fasting insulin (FINS) and leptin levels." | 7.85 | Effects of Exercise Intervention on Preventing Letrozole-Exposed Rats From Polycystic Ovary Syndrome. ( Cao, SF; Hu, WL; Jiang, LY; Wu, MM, 2017) |
| "Here we hypothesized that exercise in dihydrotestosterone (DHT) or letrozole (LET)-induced polycystic ovary syndrome mouse models improves impaired insulin and glucose metabolism, adipose tissue morphology, and expression of genes related to adipogenesis, lipid metabolism, Notch pathway and browning in inguinal and mesenteric fat." | 7.85 | Exercise differentially affects metabolic functions and white adipose tissue in female letrozole- and dihydrotestosterone-induced mouse models of polycystic ovary syndrome. ( Benrick, A; Carlström, M; Cushman, SW; Fornes, R; Hu, M; Ivarsson, N; Maciel, GAR; Maliqueo, M; Marcondes, RR; Stener-Victorin, E; Stenkula, KG, 2017) |
| "This study was to investigate the effects of cisplatin (CDDP) and letrozole on surgically induced endometriosis and comparison of the two drugs in a rat model." | 7.83 | Effects of cisplatin and letrozole on surgically induced endometriosis and comparison of the two medications in a rat model. ( He, Z; Lang, J; Li, Z; Liu, H; Zhang, G, 2016) |
| "To explore the effect of compound malt pills (CMP) on polycystic ovarian syndrome (PCOS) rat model induced by letrozole and the underlying mechanisms." | 7.83 | [Effects of compound malt pills on expressions of ERα and ERβ in ovaries of rats with letrozole-induced polycystic ovarian syndrome]. ( Chen, R; Lan, N; Wang, S; Yang, Y, 2016) |
| "Our aim was to investigate the effects of metformin and letrozole on experimentally induced endometriosis in a rat model." | 7.76 | The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model. ( Basbug, M; Oner, G; Ozcelik, B; Ozgun, MT; Ozturk, F; Serin, IS, 2010) |
| "The antiestrogen tamoxifen has potent activity against estrogen receptor-positive breast cancer, but two nonsteroidal aromatase inhibitors, letrozole and anastrozole, show considerable advantages over tamoxifen with respect to patient survival and tolerability." | 7.72 | Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A, 2004) |
| "Tamoxifen treatment inhibited breast cancer cell growth and increased BMD but caused uterine hypertrophy in this preclinical model of postmenopausal breast cancer." | 7.72 | Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. ( Barrett, JC; Berrigan, D; Brodie, A; Hursting, SD; Jelovac, D; Macedo, L; Núñez, NP; Perkins, SN, 2004) |
| "The letrozole-treated mice showed a disrupted estrous cycle and were arrested in the diestrus phase." | 5.62 | Cysteine-Cysteine Motif Chemokine Receptor 5 Expression in Letrozole-Induced Polycystic Ovary Syndrome Mice. ( Chen, CW; Chen, KH; Chen, LK; Ho, CH; Hwang, JL; Juan, CC; Liu, PS; Seow, KM; Wang, PH, 2021) |
| "The effective treatment of polycystic ovary syndrome (PCOS)-related hormonal disorders necessitates the development of novel treatment strategies." | 5.62 | Beneficial phytoestrogenic effects of resveratrol on polycystic ovary syndromein rat model. ( Chen, L; Gai, S; Li, F; Liu, X; Shan, Y; Wang, S; Zhang, N; Zhao, D; Zhuang, L, 2021) |
| "A rat model of PCOS-IR was established using a high-fat diet (49 d) combined with letrozole (1 mg/kg·d, for 28 d)." | 5.62 | Effects of total flavonoids from Eucommia ulmoides Oliv. leaves on polycystic ovary syndrome with insulin resistance model rats induced by letrozole combined with a high-fat diet. ( Li, CX; Li, M; Miao, MS; Peng, MF; Ren, Z; Song, YG; Tian, S, 2021) |
| " The methods for establishing PCOS-IR animal model include using dehydroepiandrosterone (DHEA) and sodium prasterone sulfate subcutaneous injection, testosterone propionate combined with high-fat diet, and so on." | 5.56 | A Rat Model of Polycystic Ovary Syndrome with Insulin Resistance Induced by Letrozole Combined with High Fat Diet. ( Wang, MX; Xu, X; Yin, Q, 2020) |
| "Letrozole (1 mg/kg) was administered orally for a period of 28 days to induce PCOS." | 5.56 | The effects of thylakoid-rich spinach extract and aqueous extract of caraway (Carum carvi L.) in letrozole-induced polycystic ovarian syndrome rats. ( Ekramzadeh, M; Golmakani, MT; Koohpeyma, F; Sherafatmanesh, S; Tanideh, N, 2020) |
| "Polycystic ovary syndrome is one of the most common causes of female infertility, affecting 5-10% of the population." | 5.51 | Ocimum kilimandscharicum L. restores ovarian functions in letrozole - induced Polycystic Ovary Syndrome (PCOS) in rats: Comparison with metformin. ( AbdelMaksoud, S; El-Bahy, AA; Handoussa, H; Khaled, N; Radwan, R, 2019) |
| "Letrozole was administered orally (1 mg kg-1) to induce PCOS condition in Wistar female rats for a period of 2-3 weeks followed by a dose of melatonin (200 µg/100 g b." | 5.48 | Therapeutic Efficacy of Melatonin Against Polycystic Ovary Syndrome (PCOS) Induced by Letrozole in Wistar Rat. ( Ahmad Hajam, Y; Basheer, M; Ghosh, H; Rai, S, 2018) |
| "Letrozole treatment was associated with a time-dependent shift in the gut microbiome and a substantial reduction in overall species and phylogenetic richness." | 5.43 | The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome. ( Kelley, ST; Rivera, AJ; Skarra, DV; Thackray, VG, 2016) |
| "Metformin was also given as a standard control to one of the rat groups." | 5.43 | Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats. ( Afsar, T; Ain, QU; Almajwal, A; Jahan, S; Mehboob, A; Munir, F; Razak, S; Shaheen, G; Ullah, H, 2016) |
| "The letrozole model group is a good animal model for the study of AMH in PCOS patients with obesity or insulin resistance." | 5.40 | Expression of anti-Müllerian hormone in letrozole rat model of polycystic ovary syndrome. ( Du, DF; Du, MR; Fang, F; Li, XL, 2014) |
| "Combined application of tamoxifen and radiotherapy improves survival and local control in breast cancer." | 4.83 | [Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment]. ( Fodor, J, 2006) |
| "The present study aimed to investigate whether time-restricted feeding (TRF) ameliorates metabolic and reproductive phenotypes in a letrozole-induced mouse model of polycystic ovary syndrome (PCOS)." | 4.31 | Effects of time-restricted feeding on letrozole-induced mouse model of polycystic ovary syndrome. ( Han, YI; Jeong, HG; Kim, T; Lee, HJ; Nam, S; Park, H; Ryu, KJ, 2023) |
| " To that end, we have established a Swiss albino mouse model of PCOS based on 3 weeks of daily treatment with letrozole (50 μg/day; intraperitoneal) and dehydroepiandrosterone (DHEA, 6 mg/100 g body weight; subcutaneous) in 5-week-old female mice fed on normal or high-fat diet (HFD)." | 4.12 | Distinctions in PCOS Induced by Letrozole Vs Dehydroepiandrosterone With High-fat Diet in Mouse Model. ( Adiga, SK; Bakkum-Gamez, J; Chang, AY; DeStephano, C; Kalthur, G; Kalthur, SG; Kannan, N; Kundapur, SD; Mutalik, S; Nayak, G; Panchanan, G; Poojary, PS; Rao, A; Sherman, M; Zhao, Y, 2022) |
| "To assess the protective effect of dark chocolate (DC) on the letrozole-induced rat model of polycystic ovary syndrome (PCOS)." | 4.12 | Protective efficacy of dark chocolate in letrozole-induced ovary toxicity model rats: hormonal, biochemical, and histopathological investigation. ( Hesami, S; Hosseini, A; Mirazi, N; Nourian, A, 2022) |
| "Letrozole-treated rats showed successful induction of PCOS, confirmed by histopathology and significantly increased body weight, testosterone, insulin, AMH, and MDA, and decreased SOD." | 4.12 | Fenofibrate ameliorates letrozole-induced polycystic ovary in rats via modulation of PPARα and TNFα/CD95 pathway. ( El-Hussieny, M; Morsy, MA; Nair, AB; Refaie, MMM; Venugopala, KN; Zenhom, NM, 2022) |
| "The objective of the present study was to investigate the effect of melatonin and L-thyroxine (T4) on the expression of various receptors, and some metabolic, reproductive, and gonadotropic hormones in letrozole-induced polycystic ovary syndrome (PCOS) in rats." | 4.12 | Differential expression and interaction of melatonin and thyroid hormone receptors with estrogen receptor α improve ovarian functions in letrozole-induced rat polycystic ovary syndrome. ( Brown, GM; Cardinali, DP; Ghosh, H; Manzar, MD; Pandi-Perumal, SR; Rai, S; Reiter, RJ, 2022) |
| " In this regard, studies have demonstrated that Aloe vera gel has the potential to modulate steroidogenic activity in letrozole induced polycystic ovary syndrome (PCOS) rat." | 4.12 | Partially purified non-polar phytocomponents from Aloe barbadensis Mill. gel restores metabolic and reproductive comorbidities in letrozole-induced polycystic ovary syndrome rodent model- an "in-vivo" study. ( Dey, A; Dhadhal, S; Maharjan, R; Nagar, PS; Nampoothiri, L, 2022) |
| "The impact of low-dose spironolactone (LSPL) on polycystic ovarian syndrome (PCOS)-associated cardio-renal disorder is unknown." | 4.12 | Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model. ( Akintayo, CO; Areloegbe, SE; Aturamu, A; Olaniyi, KS; Oniyide, AA; Peter, MU, 2022) |
| " Twenty-four female Wistar rats were allocated into three groups: control; polycystic ovary syndrome (PCOS) in which PCOS was induced by letrozole, orally in a dose of 1 mg/kg once daily for 3 weeks; and ADM group in which ADM was injected intraperitonally in a dose of 3." | 4.02 | Potential effect of adrenomedullin on metabolic and endocrinal dysfunctions in the experimentally induced polycystic ovary: Targeting implication of endoplasmic reticulum stress. ( Alghazaly, GM; Barhoma, RA; El-Saka, MH; Elsaadany, A; Elshwaikh, S; Ibrahim, RR; Madi, NM; Marea, KE, 2021) |
| " Liraglutide has favourable neuroprotective effects that may protect against the possible cognitive dysfunction in PCOS." | 4.02 | Liraglutide mends cognitive impairment by averting Notch signaling pathway overexpression in a rat model of polycystic ovary syndrome. ( Abdel Salam, RM; Ahmed, MAE; Eltarzy, MA; Saad, MA, 2021) |
| " deltoidea at the dose of 500 and 1000 mg/kg/day reduced insulin resistance, obesity indices, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL), malondialdehyde (MDA), testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) to near-normal levels in PCOS rats." | 4.02 | Ficus deltoidea ameliorates biochemical, hormonal, and histomorphometric changes in letrozole-induced polycystic ovarian syndrome rats. ( Goh, YM; Hashim, N; Haslan, MA; Samsulrizal, N; Shirazi, FH; Zin, NSNM, 2021) |
| "The present study was conducted to investigate the therapeutic effects of a potent polyphenol, fisetin, on the letrozole-induced rat model of polycystic ovary syndrome (PCOS)." | 4.02 | Ameliorative effects of fisetin in letrozole-induced rat model of polycystic ovary syndrome. ( Khadem-Ansari, MH; Mihanfar, A; Nouri, M; Roshangar, L, 2021) |
| "BACKGROUND The aim of this study was to explore whether letrozole and high-fat diets (HFD) can induce obese insulin-resistant polycystic ovary syndrome (PCOS) with all reproductive and metabolic phenotypes in a rat model." | 3.96 | Letrozole Rat Model Mimics Human Polycystic Ovarian Syndrome and Changes in Insulin Signal Pathways. ( Dun, J; Huang, L; Huang, M; Ji, F; Lin, Q; Lin, Y; Xu, J; Yang, J; You, X; Zhang, J, 2020) |
| " In addition, the minimal weight gain and lack of insulin resistance in adult female mice after letrozole treatment indicates that this model may be useful for investigating the effects of hyperandrogenemia on the hypothalamic-pituitary-gonadal axis and the periphery without the influence of substantial metabolic dysregulation." | 3.91 | Letrozole treatment of adult female mice results in a similar reproductive phenotype but distinct changes in metabolism and the gut microbiome compared to pubertal mice. ( Anvar, AR; Ho, BS; Kelley, ST; Sau, L; Skarra, DV; Thackray, VG; Torres, PJ, 2019) |
| " The study investigated the effects of quercetin in a letrozole induced rat model of polycystic ovarian syndrome, which displayed both clinical and metabolic features as in PCOS women." | 3.88 | Therapeutic potentials of Quercetin in management of polycystic ovarian syndrome using Letrozole induced rat model: a histological and a biochemical study. ( Abid, A; Afsar, T; Almajwal, A; Jahan, S; Khalid, S; Razak, S; Shaheen, G, 2018) |
| "Here we hypothesized that exercise in dihydrotestosterone (DHT) or letrozole (LET)-induced polycystic ovary syndrome mouse models improves impaired insulin and glucose metabolism, adipose tissue morphology, and expression of genes related to adipogenesis, lipid metabolism, Notch pathway and browning in inguinal and mesenteric fat." | 3.85 | Exercise differentially affects metabolic functions and white adipose tissue in female letrozole- and dihydrotestosterone-induced mouse models of polycystic ovary syndrome. ( Benrick, A; Carlström, M; Cushman, SW; Fornes, R; Hu, M; Ivarsson, N; Maciel, GAR; Maliqueo, M; Marcondes, RR; Stener-Victorin, E; Stenkula, KG, 2017) |
| "Soy isoflavones (100 mg/kg) treatment significantly altered the letrozole-induced PCOS symptoms as observed by decreased body weight gain (p < 0." | 3.85 | Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism. ( Balaji, B; M, SS; Rajan, RK, 2017) |
| " Polycystic ovary syndrome was induced by letrozole administration, and animals presented with obesity, sex hormone disorder, no ovulation, large cystic follicles, and increasing fasting insulin (FINS) and leptin levels." | 3.85 | Effects of Exercise Intervention on Preventing Letrozole-Exposed Rats From Polycystic Ovary Syndrome. ( Cao, SF; Hu, WL; Jiang, LY; Wu, MM, 2017) |
| "To explore the effect of compound malt pills (CMP) on polycystic ovarian syndrome (PCOS) rat model induced by letrozole and the underlying mechanisms." | 3.83 | [Effects of compound malt pills on expressions of ERα and ERβ in ovaries of rats with letrozole-induced polycystic ovarian syndrome]. ( Chen, R; Lan, N; Wang, S; Yang, Y, 2016) |
| "This study was to investigate the effects of cisplatin (CDDP) and letrozole on surgically induced endometriosis and comparison of the two drugs in a rat model." | 3.83 | Effects of cisplatin and letrozole on surgically induced endometriosis and comparison of the two medications in a rat model. ( He, Z; Lang, J; Li, Z; Liu, H; Zhang, G, 2016) |
| "We examined the efficacy of chemoendocrine therapy using capecitabine as a chemotherapeutic agent in premenopausal and postmenopausal models with estrogen receptor (ER)-positive human breast cancer xenografts." | 3.78 | Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts. ( Evans, DB; Hayashi, S; Kataoka, M; Kondoh, K; Mori, K; Moriya, Y; Sawada, N; Yamaguchi, Y; Yasuno, H, 2012) |
| "Letrozole and ETA caused a regression on the implant size in experimental endometriosis." | 3.77 | Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model. ( Baser, I; Ceyhan, ST; Fidan, U; Ide, T; Kilic, S; Onguru, O; Yaman, H, 2011) |
| "We explored the effects of combination of acupuncture and Chinese medicinal herbs in treating model rats with polycystic ovarian syndrome (PCOS) and to explore whether acupuncture has positive effects on the absorption of salvianolic acid B in the extracts of a Chinese medicine formula when treating the model rats." | 3.77 | Combination of acupuncture and chinese medicinal herbs in treating model rats with polycystic ovary syndrome. ( Fang, JQ; Ma, RJ; Qu, F; Yang, DH; Zhou, J, 2011) |
| "Our aim was to investigate the effects of metformin and letrozole on experimentally induced endometriosis in a rat model." | 3.76 | The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model. ( Basbug, M; Oner, G; Ozcelik, B; Ozgun, MT; Ozturk, F; Serin, IS, 2010) |
| "The antiestrogen tamoxifen has potent activity against estrogen receptor-positive breast cancer, but two nonsteroidal aromatase inhibitors, letrozole and anastrozole, show considerable advantages over tamoxifen with respect to patient survival and tolerability." | 3.72 | Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A, 2004) |
| "Tamoxifen treatment inhibited breast cancer cell growth and increased BMD but caused uterine hypertrophy in this preclinical model of postmenopausal breast cancer." | 3.72 | Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. ( Barrett, JC; Berrigan, D; Brodie, A; Hursting, SD; Jelovac, D; Macedo, L; Núñez, NP; Perkins, SN, 2004) |
| "Endometriosis is defined as the growth of endometrial tissue outside of the uterine cavity." | 2.47 | The emerging use of aromatase inhibitors for endometriosis treatment. ( Nothnick, WB, 2011) |
| "When letrozole was combined with the pure antiestrogen fulvestrant, which down-regulates ER, the combination was extremely effective." | 2.43 | Therapeutic observations in MCF-7 aromatase xenografts. ( Brodie, A; Goloubeva, O; Jelovac, D; Macedo, L; Sabnis, G; Tilghman, S, 2005) |
| "Treatment with letrozole caused hyperandrogenism, hypoestrogenism, hyperinsulinemia and multiple ovarian cysts/degenerated follicles." | 1.91 | Protective Role of Acetate Against Depressive-Like Behaviour Associated with Letrozole-Induced PCOS Rat Model: Involvement of HDAC2 and DNA Methylation. ( Areloegbe, SE; Olaniyi, KS; Wolugbom, JA, 2023) |
| "In letrozole-treated rats, glycolysis levels were found to be increased in the heart." | 1.72 | Letrozole Accelerates Metabolic Remodeling through Activation of Glycolysis in Cardiomyocytes: A Role beyond Hormone Regulation. ( Heo, JH; Hong, EJ; Jo, SL; Lee, HW; Lee, SR; Yang, H, 2022) |
| " Following plasma letrozole dosage at the end of the experiment (day 73), only rats with at least 90 ng/ml of letrozole were considered significantly exposed to letrozole (OVX + high LTZ group), whereas treated animals with less than 90 ng/ml were pooled in the OVX + low LTZ group." | 1.62 | A new clinically-relevant rat model of letrozole-induced chronic nociceptive disorders. ( Amode, R; Balayssac, D; Collin, A; Eschalier, A; Guillet, C; Pereira, B; Richard, D; Vein, J; Wittrant, Y, 2021) |
| "Polycystic ovary syndrome is a common reproductive disorder in the female of reproductive age, which is characterized by hyperandrogenism, insulin resistance, cystic ovary and infertility." | 1.62 | Inhibition of visfatin by FK866 mitigates pathogenesis of cystic ovary in letrozole-induced hyperandrogenised mice. ( Annie, L; Gurusubramanian, G; Roy, VK, 2021) |
| "A rat model of PCOS-IR was established using a high-fat diet (49 d) combined with letrozole (1 mg/kg·d, for 28 d)." | 1.62 | Effects of total flavonoids from Eucommia ulmoides Oliv. leaves on polycystic ovary syndrome with insulin resistance model rats induced by letrozole combined with a high-fat diet. ( Li, CX; Li, M; Miao, MS; Peng, MF; Ren, Z; Song, YG; Tian, S, 2021) |
| "The effective treatment of polycystic ovary syndrome (PCOS)-related hormonal disorders necessitates the development of novel treatment strategies." | 1.62 | Beneficial phytoestrogenic effects of resveratrol on polycystic ovary syndromein rat model. ( Chen, L; Gai, S; Li, F; Liu, X; Shan, Y; Wang, S; Zhang, N; Zhao, D; Zhuang, L, 2021) |
| "The letrozole-treated mice showed a disrupted estrous cycle and were arrested in the diestrus phase." | 1.62 | Cysteine-Cysteine Motif Chemokine Receptor 5 Expression in Letrozole-Induced Polycystic Ovary Syndrome Mice. ( Chen, CW; Chen, KH; Chen, LK; Ho, CH; Hwang, JL; Juan, CC; Liu, PS; Seow, KM; Wang, PH, 2021) |
| " The animals received resveratrol at a dosage of 20 mg/kg and 30 mg/kg for the next 30 days." | 1.62 | The effectiveness of resveratrol in treatment of PCOS on the basis of experimental model in rats. ( Abashova, E; Borodina, V; Bulgakova, O; Tral, T; Yarmolinskaya, M, 2021) |
| "Letrozole-treated females demonstrate multiple PCOS-like phenotypes, including polycystic ovaries, anovulation, and elevated circulating testosterone and LH, assayed in "one-off" measures." | 1.56 | Hyperactive LH Pulses and Elevated Kisspeptin and NKB Gene Expression in the Arcuate Nucleus of a PCOS Mouse Model. ( Esparza, LA; Ho, BS; Kauffman, AS; Schafer, D; Thackray, VG, 2020) |
| "Letrozole (1 mg/kg) was administered orally for a period of 28 days to induce PCOS." | 1.56 | The effects of thylakoid-rich spinach extract and aqueous extract of caraway (Carum carvi L.) in letrozole-induced polycystic ovarian syndrome rats. ( Ekramzadeh, M; Golmakani, MT; Koohpeyma, F; Sherafatmanesh, S; Tanideh, N, 2020) |
| " The methods for establishing PCOS-IR animal model include using dehydroepiandrosterone (DHEA) and sodium prasterone sulfate subcutaneous injection, testosterone propionate combined with high-fat diet, and so on." | 1.56 | A Rat Model of Polycystic Ovary Syndrome with Insulin Resistance Induced by Letrozole Combined with High Fat Diet. ( Wang, MX; Xu, X; Yin, Q, 2020) |
| "Letrozole was used to produce a PCOS rat model and a 4-week-strain-intervention was performed." | 1.56 | Lactic acid bacteria alleviate polycystic ovarian syndrome by regulating sex hormone related gut microbiota. ( Chen, W; He, Y; Li, X; Wang, G; Wang, Q; Zhang, H; Zhao, J, 2020) |
| "Polycystic ovary syndrome is one of the most common causes of female infertility, affecting 5-10% of the population." | 1.51 | Ocimum kilimandscharicum L. restores ovarian functions in letrozole - induced Polycystic Ovary Syndrome (PCOS) in rats: Comparison with metformin. ( AbdelMaksoud, S; El-Bahy, AA; Handoussa, H; Khaled, N; Radwan, R, 2019) |
| "Letrozole was administered orally (1 mg kg-1) to induce PCOS condition in Wistar female rats for a period of 2-3 weeks followed by a dose of melatonin (200 µg/100 g b." | 1.48 | Therapeutic Efficacy of Melatonin Against Polycystic Ovary Syndrome (PCOS) Induced by Letrozole in Wistar Rat. ( Ahmad Hajam, Y; Basheer, M; Ghosh, H; Rai, S, 2018) |
| "Flutamide treatment in LET females reversed elevated T levels and restored ovarian expression of Cyp17a1 (critical for androgen synthesis) to normal levels." | 1.48 | Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS. ( Malik, S; Mellon, PL; Ryan, GE, 2018) |
| "Metformin was also given as a standard control to one of the rat groups." | 1.43 | Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats. ( Afsar, T; Ain, QU; Almajwal, A; Jahan, S; Mehboob, A; Munir, F; Razak, S; Shaheen, G; Ullah, H, 2016) |
| " Repeated injection of 5mg/kg letrozole in male rats produced mechanical, but not thermal, hypersensitivity that extinguished when drug dosing was stopped." | 1.43 | Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons. ( Duarte, DB; Flockhart, DA; Robarge, JD; Shariati, B; Vasko, MR; Wang, R, 2016) |
| "Letrozole treatment was associated with a time-dependent shift in the gut microbiome and a substantial reduction in overall species and phylogenetic richness." | 1.43 | The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome. ( Kelley, ST; Rivera, AJ; Skarra, DV; Thackray, VG, 2016) |
| "Obesity is a risk factor for breast cancer progression." | 1.42 | A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors. ( Goloubeva, O; McLenithan, J; Sabnis, G; Schech, A; Yu, S, 2015) |
| "Here, we examined tumor-induced mechanical hyperalgesia and cold allodynia, and changes in Glial fibrillary acid protein (GFAP) and aromatase expression in murine models of painful and non-painful bone cancer." | 1.42 | Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor. ( Beitz, AJ; Lee, JH; Michlitsch, KS; O'Brien, EE; Smeester, BA, 2015) |
| "The letrozole model group is a good animal model for the study of AMH in PCOS patients with obesity or insulin resistance." | 1.40 | Expression of anti-Müllerian hormone in letrozole rat model of polycystic ovary syndrome. ( Du, DF; Du, MR; Fang, F; Li, XL, 2014) |
| "Entinostat treatment reduced the association of the Her-2 protein with HSP-90, possibly by reducing the stability of Her-2 protein." | 1.39 | HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. ( Brodie, AH; Goloubeva, OG; Kazi, AA; Sabnis, GJ; Shah, P, 2013) |
| "BC cell lines expressing aromatase (AROM) and modeling endocrine-sensitive (MCF7-AROM1) and human epidermal growth factor receptor 2 (HER2)-dependent de novo resistant disease (BT474-AROM3) and long-term estrogen-deprived (LTED) MCF7 cells that had acquired resistance associated with HER2 overexpression were treated in vitro and as subcutaneous xenografts with everolimus (RAD001-mTORC1 inhibitor), in combination with tamoxifen or letrozole." | 1.38 | Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. ( A'Hern, R; Dowsett, M; Evans, DB; Farmer, I; Ghazoui, Z; Guest, S; Johnston, SR; Lane, HA; Martin, LA; Pancholi, S; Ribas, R; Thornhill, AM; Weigel, MT, 2012) |
| "Treatment with anastrozole or letrozole was started on either postoperative day 1 or 28 and continued for 4 weeks." | 1.36 | Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis. ( Barañao, RI; Bilotas, M; Meresman, G; Stella, I; Sueldo, C, 2010) |
| "Letrozole treatment induced an increase in the expression of AR, StAR and 3beta-HSD and a decrease in ERbeta." | 1.35 | Disruption in the expression and immunolocalisation of steroid receptors and steroidogenic enzymes in letrozole-induced polycystic ovaries in rat. ( Alfaro, NS; Mason, JI; Ortega, HH; Salvetti, NR; Velazquez, MM; Zurvarra, FM, 2009) |
| "Changes in breast cancer cell biology following hormonal treatment have been claimed as promising predictor markers of clinical benefit even outperforming clinical response." | 1.35 | Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer. ( Aguilar, H; Capellà, G; Dowsett, M; Germà-Lluch, JR; Martin, LA; Solé, X; Urruticoechea, A, 2008) |
| "All letrozole rats were anovulatory and developed polycystic ovaries with structural changes strikingly similar to those in human PCOS." | 1.34 | A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. ( Cajander, S; Holmäng, A; Lönn, M; Lystig, T; Mannerås, L; Seleskovic, Z; Stener-Victorin, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.86) | 18.2507 |
| 2000's | 11 (9.48) | 29.6817 |
| 2010's | 50 (43.10) | 24.3611 |
| 2020's | 54 (46.55) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Ghosh, H | 2 |
| Rai, S | 2 |
| Manzar, MD | 1 |
| Pandi-Perumal, SR | 1 |
| Brown, GM | 1 |
| Reiter, RJ | 1 |
| Cardinali, DP | 1 |
| Liyanage, GSG | 1 |
| Inoue, R | 1 |
| Fujitani, M | 1 |
| Ishijima, T | 1 |
| Shibutani, T | 1 |
| Abe, K | 1 |
| Kishida, T | 1 |
| Okada, S | 1 |
| Haslan, MA | 1 |
| Samsulrizal, N | 1 |
| Hashim, N | 1 |
| Zin, NSNM | 1 |
| Shirazi, FH | 1 |
| Goh, YM | 1 |
| Yarmolinskaya, M | 1 |
| Bulgakova, O | 1 |
| Abashova, E | 1 |
| Borodina, V | 1 |
| Tral, T | 1 |
| Refaie, MMM | 2 |
| El-Hussieny, M | 2 |
| Abdelraheem, WM | 1 |
| Seow, KM | 1 |
| Liu, PS | 1 |
| Chen, KH | 1 |
| Chen, CW | 1 |
| Chen, LK | 1 |
| Ho, CH | 1 |
| Hwang, JL | 1 |
| Wang, PH | 1 |
| Juan, CC | 1 |
| Heo, JH | 1 |
| Lee, SR | 2 |
| Jo, SL | 1 |
| Yang, H | 3 |
| Lee, HW | 3 |
| Hong, EJ | 2 |
| He, Y | 2 |
| Mei, L | 1 |
| Wang, L | 2 |
| Li, X | 3 |
| Zhao, J | 3 |
| Zhang, H | 3 |
| Chen, W | 2 |
| Wang, G | 2 |
| Wu, YY | 1 |
| Li, SY | 1 |
| Zhu, HQ | 1 |
| Zhuang, ZM | 1 |
| Shao, M | 1 |
| Chen, FL | 1 |
| Liu, CS | 1 |
| Tang, QF | 1 |
| Dey, A | 1 |
| Dhadhal, S | 1 |
| Maharjan, R | 1 |
| Nagar, PS | 1 |
| Nampoothiri, L | 1 |
| Zhang, Y | 1 |
| Xu, L | 1 |
| Ibrahim, YF | 1 |
| Alorabi, M | 1 |
| Abdelzaher, WY | 1 |
| Toni, ND | 1 |
| Thabet, K | 1 |
| Hegazy, A | 1 |
| Bahaa, HA | 1 |
| Batiha, GE | 1 |
| Welson, NN | 1 |
| Morsy, MA | 2 |
| Venugopala, KN | 2 |
| Abdel-Aziz, AM | 1 |
| Olaniyi, KS | 7 |
| Areloegbe, SE | 5 |
| Peter, MU | 1 |
| Akintayo, CO | 1 |
| Oniyide, AA | 3 |
| Aturamu, A | 2 |
| Poojary, PS | 1 |
| Nayak, G | 1 |
| Panchanan, G | 1 |
| Rao, A | 1 |
| Kundapur, SD | 1 |
| Kalthur, SG | 1 |
| Mutalik, S | 1 |
| Adiga, SK | 1 |
| Zhao, Y | 3 |
| Bakkum-Gamez, J | 1 |
| Chang, AY | 1 |
| DeStephano, C | 1 |
| Sherman, M | 1 |
| Kannan, N | 1 |
| Kalthur, G | 1 |
| Mirazi, N | 1 |
| Hesami, S | 1 |
| Nourian, A | 1 |
| Hosseini, A | 1 |
| Wolugbom, JA | 1 |
| Zenhom, NM | 1 |
| Nair, AB | 1 |
| Kirici, P | 2 |
| Kaplan, S | 2 |
| Annac, E | 2 |
| Tanriverdi, ES | 2 |
| Cagiran, FT | 2 |
| Kali, Z | 2 |
| Mavral, N | 2 |
| Taskapan, MC | 2 |
| Butt, MA | 1 |
| Shafique, HM | 1 |
| Mustafa, M | 1 |
| Moghul, NB | 1 |
| Munir, A | 1 |
| Shamas, U | 1 |
| Tabassum, S | 1 |
| Kiyani, MM | 1 |
| Ryu, KJ | 1 |
| Park, H | 1 |
| Han, YI | 1 |
| Lee, HJ | 1 |
| Nam, S | 1 |
| Jeong, HG | 1 |
| Kim, T | 1 |
| Elshamy, AM | 1 |
| Shatat, D | 1 |
| AbuoHashish, NA | 1 |
| Safa, MAE | 1 |
| Elgharbawy, N | 1 |
| Ibrahim, HA | 1 |
| Barhoma, RAE | 1 |
| Eltabaa, EF | 1 |
| Ahmed, AS | 1 |
| Shalaby, AM | 1 |
| Alabiad, MA | 1 |
| Alorini, M | 1 |
| Ibrahim, RR | 2 |
| Ul Haq Shah, MZ | 1 |
| Shrivastava, VK | 1 |
| Mir, MA | 1 |
| Rashid, R | 1 |
| Tripathi, R | 1 |
| Singh, A | 1 |
| Sarkar, S | 1 |
| Kawale, A | 1 |
| Bader, GN | 1 |
| Gupta, S | 1 |
| Gupta, RK | 1 |
| Jha, RK | 1 |
| Decourt, C | 1 |
| Watanabe, Y | 1 |
| Evans, MC | 1 |
| Inglis, MA | 1 |
| Fisher, LC | 1 |
| Jasoni, CL | 1 |
| Campbell, RE | 1 |
| Anderson, GM | 1 |
| Zhou, J | 2 |
| Qiu, X | 1 |
| Chen, X | 1 |
| Ma, S | 1 |
| Chen, Z | 1 |
| Wang, R | 3 |
| Tian, Y | 1 |
| Jiang, Y | 2 |
| Fan, L | 1 |
| Wang, J | 1 |
| Eepho, OI | 1 |
| Bashir, AM | 1 |
| Owolabi, OV | 1 |
| Ajadi, IO | 1 |
| Fafure, AA | 1 |
| Ajadi, MB | 1 |
| Arroyo, P | 2 |
| Ho, BS | 4 |
| Sau, L | 3 |
| Kelley, ST | 4 |
| Thackray, VG | 5 |
| Esparza, LA | 1 |
| Schafer, D | 1 |
| Kauffman, AS | 1 |
| Ding, Z | 1 |
| Chen, A | 2 |
| Yao, Y | 1 |
| Wang, X | 1 |
| Yan, L | 1 |
| Cai, H | 1 |
| Sun, H | 1 |
| Zhang, D | 2 |
| Pi, C | 1 |
| Cai, L | 1 |
| Liu, Y | 2 |
| Du, W | 1 |
| Yang, W | 1 |
| Xie, J | 1 |
| Wang, Q | 1 |
| Wang, MX | 1 |
| Yin, Q | 1 |
| Xu, X | 2 |
| Xu, J | 2 |
| Dun, J | 1 |
| Yang, J | 1 |
| Zhang, J | 2 |
| Lin, Q | 1 |
| Huang, M | 1 |
| Ji, F | 1 |
| Huang, L | 1 |
| You, X | 1 |
| Lin, Y | 1 |
| Sherafatmanesh, S | 1 |
| Ekramzadeh, M | 1 |
| Tanideh, N | 1 |
| Golmakani, MT | 1 |
| Koohpeyma, F | 2 |
| Marbouti, L | 1 |
| Zahmatkesh, M | 1 |
| Riahi, E | 1 |
| Shafiee Sabet, M | 1 |
| Zhang, N | 1 |
| Zhuang, L | 1 |
| Gai, S | 1 |
| Shan, Y | 1 |
| Wang, S | 2 |
| Li, F | 1 |
| Chen, L | 2 |
| Zhao, D | 1 |
| Liu, X | 1 |
| Mvondo, MA | 1 |
| Mzemdem Tsoplfack, FI | 1 |
| Awounfack, CF | 1 |
| Njamen, D | 1 |
| Saad, MA | 1 |
| Eltarzy, MA | 1 |
| Abdel Salam, RM | 1 |
| Ahmed, MAE | 1 |
| Luo, J | 1 |
| Qi, Q | 1 |
| Chen, Y | 2 |
| Wang, Y | 2 |
| Xie, Q | 1 |
| Adeyanju, OA | 1 |
| Ojulari, LS | 1 |
| Omoaghe, AO | 1 |
| Olaiya, OE | 1 |
| El-Saka, MH | 1 |
| Barhoma, RA | 1 |
| Elsaadany, A | 1 |
| Alghazaly, GM | 1 |
| Elshwaikh, S | 1 |
| Marea, KE | 1 |
| Madi, NM | 1 |
| Khajouei, A | 1 |
| Hosseini, E | 1 |
| Abdizadeh, T | 1 |
| Kian, M | 1 |
| Ghasemi, S | 1 |
| Peng, MF | 1 |
| Tian, S | 1 |
| Song, YG | 1 |
| Li, CX | 1 |
| Miao, MS | 1 |
| Ren, Z | 1 |
| Li, M | 1 |
| Bries, AE | 1 |
| Webb, JL | 1 |
| Vogel, B | 1 |
| Carrillo, C | 1 |
| Keating, AF | 1 |
| Pritchard, SK | 1 |
| Roslan, G | 1 |
| Miller, JW | 1 |
| Schalinske, KL | 1 |
| Annie, L | 1 |
| Gurusubramanian, G | 1 |
| Roy, VK | 1 |
| Helal, BAF | 1 |
| Ismail, GM | 1 |
| Nassar, SE | 1 |
| Zeid, AAA | 1 |
| Kausar, F | 1 |
| Rather, MA | 1 |
| Bashir, SM | 1 |
| Alsaffar, RM | 1 |
| Nabi, SU | 1 |
| Ali, SI | 1 |
| Goswami, P | 1 |
| Ahmad, A | 1 |
| Rashid, S | 1 |
| Wali, AF | 1 |
| Collin, A | 1 |
| Vein, J | 1 |
| Wittrant, Y | 1 |
| Pereira, B | 1 |
| Amode, R | 1 |
| Guillet, C | 1 |
| Richard, D | 1 |
| Eschalier, A | 1 |
| Balayssac, D | 1 |
| Emam, SR | 1 |
| Abd-Elsalam, RM | 1 |
| Azouz, AA | 1 |
| Ali, SE | 1 |
| El Badawy, SA | 1 |
| Ibrahim, MA | 1 |
| Hassan, BB | 1 |
| Issa, MY | 1 |
| Elmosalamy, SH | 1 |
| Hansda, SR | 1 |
| Haldar, C | 1 |
| Liu, J | 1 |
| Zhang, W | 1 |
| Mihanfar, A | 1 |
| Nouri, M | 1 |
| Roshangar, L | 1 |
| Khadem-Ansari, MH | 1 |
| Marcondes, RR | 2 |
| Maliqueo, M | 2 |
| Fornes, R | 1 |
| Benrick, A | 2 |
| Hu, M | 1 |
| Ivarsson, N | 1 |
| Carlström, M | 1 |
| Cushman, SW | 1 |
| Stenkula, KG | 1 |
| Maciel, GAR | 1 |
| Stener-Victorin, E | 3 |
| Bonilla-Becerra, SM | 1 |
| de Oliveira, MG | 1 |
| Calmasini, FB | 1 |
| Rojas-Moscoso, JA | 1 |
| Zanesco, A | 1 |
| Antunes, E | 1 |
| Borbélyová, V | 1 |
| Domonkos, E | 1 |
| Bábíčková, J | 1 |
| Tóthová, Ľ | 1 |
| Kačmárová, M | 1 |
| Uličná, O | 1 |
| Ostatníková, D | 1 |
| Hodosy, J | 1 |
| Celec, P | 1 |
| Ryan, GE | 1 |
| Malik, S | 1 |
| Mellon, PL | 1 |
| Fu, LL | 1 |
| Xu, Y | 2 |
| Li, DD | 1 |
| Dai, XW | 1 |
| Zhang, JS | 1 |
| Ming, H | 1 |
| Zhang, XY | 1 |
| Zhang, GQ | 1 |
| Ma, YL | 1 |
| Zheng, LW | 1 |
| Jahan, S | 2 |
| Abid, A | 1 |
| Khalid, S | 1 |
| Afsar, T | 2 |
| Shaheen, G | 2 |
| Almajwal, A | 2 |
| Razak, S | 2 |
| Iqbal, R | 1 |
| Jain, GK | 1 |
| Siraj, F | 1 |
| Vohora, D | 1 |
| Pyun, BJ | 1 |
| Sohn, E | 1 |
| Yu, SY | 1 |
| Lee, D | 1 |
| Jung, DH | 1 |
| Ko, BS | 1 |
| Shekarforoush, S | 1 |
| Safari, F | 1 |
| Lee, YH | 1 |
| Kwon, SW | 1 |
| Basheer, M | 1 |
| Ahmad Hajam, Y | 1 |
| Jouhari, S | 1 |
| Mohammadzadeh, A | 1 |
| Soltanghoraee, H | 1 |
| Mohammadi, Z | 1 |
| Khazali, S | 1 |
| Mirzadegan, E | 1 |
| Lakpour, N | 1 |
| Fatemi, F | 1 |
| Zafardoust, S | 1 |
| Mohazzab, A | 1 |
| Naderi, MM | 1 |
| Shao, YY | 1 |
| Chang, ZP | 1 |
| Cheng, Y | 1 |
| Wang, XC | 1 |
| Zhang, JP | 1 |
| Feng, XJ | 1 |
| Guo, YT | 1 |
| Liu, JJ | 1 |
| Hou, RG | 1 |
| Hong, Y | 1 |
| Yin, Y | 1 |
| Tan, Y | 1 |
| Hong, K | 1 |
| Zhou, H | 1 |
| Torres, PJ | 2 |
| Skarra, DV | 2 |
| Anvar, AR | 1 |
| Lang, Q | 1 |
| Yidong, X | 1 |
| Xueguang, Z | 1 |
| Sixian, W | 1 |
| Wenming, X | 1 |
| Tao, Z | 1 |
| Khaled, N | 1 |
| El-Bahy, AA | 1 |
| Radwan, R | 1 |
| Handoussa, H | 1 |
| AbdelMaksoud, S | 1 |
| Sabnis, GJ | 1 |
| Goloubeva, OG | 2 |
| Kazi, AA | 1 |
| Shah, P | 1 |
| Brodie, AH | 2 |
| Du, DF | 1 |
| Li, XL | 1 |
| Fang, F | 1 |
| Du, MR | 1 |
| Xu, XJ | 1 |
| Zhang, HF | 1 |
| Shou, XJ | 1 |
| Li, J | 2 |
| Jing, WL | 1 |
| Zhou, Y | 1 |
| Qian, Y | 1 |
| Han, SP | 1 |
| Zhang, R | 1 |
| Han, JS | 1 |
| Gong, P | 1 |
| Nwachukwu, JC | 1 |
| Srinivasan, S | 1 |
| Ko, C | 1 |
| Bagchi, MK | 1 |
| Taylor, RN | 1 |
| Korach, KS | 1 |
| Nettles, KW | 1 |
| Katzenellenbogen, JA | 1 |
| Katzenellenbogen, BS | 1 |
| Dave, N | 1 |
| Chow, LM | 1 |
| Gudelsky, GA | 1 |
| LaSance, K | 1 |
| Qi, X | 1 |
| Desai, PB | 1 |
| Gong, J | 1 |
| Wu, DB | 1 |
| Zhang, LL | 1 |
| Zhao, X | 1 |
| Rezvanfar, MA | 1 |
| Saeedi, S | 1 |
| Mansoori, P | 1 |
| Saadat, S | 1 |
| Goosheh, M | 1 |
| Shojaei Saadi, HA | 1 |
| Baeeri, M | 1 |
| Abdollahi, M | 1 |
| O'Brien, EE | 1 |
| Smeester, BA | 1 |
| Michlitsch, KS | 1 |
| Lee, JH | 1 |
| Beitz, AJ | 1 |
| Schech, A | 1 |
| Yu, S | 1 |
| Goloubeva, O | 2 |
| McLenithan, J | 1 |
| Sabnis, G | 3 |
| Rivera, AJ | 1 |
| Lan, N | 1 |
| Yang, Y | 1 |
| Chen, R | 1 |
| Robarge, JD | 1 |
| Duarte, DB | 1 |
| Shariati, B | 1 |
| Flockhart, DA | 1 |
| Vasko, MR | 1 |
| Cao, SF | 1 |
| Hu, WL | 1 |
| Wu, MM | 1 |
| Jiang, LY | 1 |
| Li, Z | 1 |
| Liu, H | 1 |
| He, Z | 1 |
| Zhang, G | 1 |
| Lang, J | 1 |
| Matsuzaki, T | 1 |
| Tungalagsuvd, A | 1 |
| Iwasa, T | 1 |
| Munkhzaya, M | 1 |
| Yanagihara, R | 1 |
| Tokui, T | 1 |
| Yano, K | 1 |
| Mayila, Y | 1 |
| Kato, T | 1 |
| Kuwahara, A | 1 |
| Matsui, S | 1 |
| Irahara, M | 1 |
| Li, C | 1 |
| Chen, S | 1 |
| Fu, L | 1 |
| Gao, S | 1 |
| Liu, Z | 1 |
| Wang, F | 1 |
| Zhu, X | 1 |
| Rao, J | 1 |
| Zhou, X | 1 |
| Johansson, J | 1 |
| Sun, M | 1 |
| Munir, F | 1 |
| Mehboob, A | 1 |
| Ain, QU | 1 |
| Ullah, H | 1 |
| Rajan, RK | 1 |
| M, SS | 1 |
| Balaji, B | 1 |
| Li, Q | 1 |
| Lao, K | 1 |
| Zurvarra, FM | 1 |
| Salvetti, NR | 1 |
| Mason, JI | 1 |
| Velazquez, MM | 1 |
| Alfaro, NS | 1 |
| Ortega, HH | 1 |
| Bilotas, M | 1 |
| Meresman, G | 1 |
| Stella, I | 1 |
| Sueldo, C | 1 |
| Barañao, RI | 1 |
| Brodie, A | 4 |
| Oner, G | 1 |
| Ozcelik, B | 1 |
| Ozgun, MT | 1 |
| Serin, IS | 1 |
| Ozturk, F | 1 |
| Basbug, M | 1 |
| Ceyhan, ST | 1 |
| Onguru, O | 1 |
| Fidan, U | 1 |
| Ide, T | 1 |
| Yaman, H | 1 |
| Kilic, S | 1 |
| Baser, I | 1 |
| Nothnick, WB | 1 |
| Meng, FT | 1 |
| Ni, RJ | 1 |
| Zhang, Z | 1 |
| Liu, YJ | 1 |
| Zhou, JN | 1 |
| Kataoka, M | 1 |
| Yamaguchi, Y | 1 |
| Moriya, Y | 1 |
| Sawada, N | 1 |
| Yasuno, H | 1 |
| Kondoh, K | 1 |
| Evans, DB | 2 |
| Mori, K | 1 |
| Hayashi, S | 1 |
| Ma, RJ | 1 |
| Fang, JQ | 1 |
| Yang, DH | 1 |
| Qu, F | 1 |
| Riedmann, EM | 1 |
| Martin, LA | 2 |
| Pancholi, S | 1 |
| Farmer, I | 1 |
| Guest, S | 1 |
| Ribas, R | 1 |
| Weigel, MT | 1 |
| Thornhill, AM | 1 |
| Ghazoui, Z | 1 |
| A'Hern, R | 1 |
| Lane, HA | 1 |
| Johnston, SR | 1 |
| Dowsett, M | 2 |
| Langoi, D | 1 |
| Pavone, ME | 1 |
| Gurates, B | 1 |
| Chai, D | 1 |
| Fazleabas, A | 1 |
| Bulun, SE | 1 |
| Long, BJ | 3 |
| Jelovac, D | 5 |
| Thiantanawat, A | 2 |
| Brodie, AM | 2 |
| Long, B | 1 |
| Handratta, V | 1 |
| MacPherson, N | 1 |
| Ragaz, J | 1 |
| Núñez, NP | 1 |
| Macedo, L | 2 |
| Berrigan, D | 1 |
| Perkins, SN | 1 |
| Hursting, SD | 1 |
| Barrett, JC | 1 |
| Tilghman, S | 1 |
| Swain, SM | 1 |
| Fodor, J | 1 |
| Goss, PE | 1 |
| Qi, S | 1 |
| Hu, H | 1 |
| Cheung, AM | 1 |
| Mannerås, L | 1 |
| Cajander, S | 1 |
| Holmäng, A | 1 |
| Seleskovic, Z | 1 |
| Lystig, T | 1 |
| Lönn, M | 1 |
| Urruticoechea, A | 1 |
| Aguilar, H | 1 |
| Solé, X | 1 |
| Capellà, G | 1 |
| Germà-Lluch, JR | 1 |
| Lu, Q | 1 |
| Grigoryev, D | 1 |
| Gimbel, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trial of Tucidinostat in Combination With Fulvestrant in Patients With Hormone-receptor Positive Advanced Breast Cancer[NCT04999540] | Phase 2 | 73 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for letrozole and Disease Models, Animal
| Article | Year |
|---|---|
The emerging use of aromatase inhibitors for endometriosis treatment.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Disease Models, Animal; Endometriosis; Endometrium; Estr | 2011 |
Therapeutic observations in MCF-7 aromatase xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Mo | 2005 |
[Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment].
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adju | 2006 |
113 other studies available for letrozole and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Differential expression and interaction of melatonin and thyroid hormone receptors with estrogen receptor α improve ovarian functions in letrozole-induced rat polycystic ovary syndrome.
Topics: Animals; Disease Models, Animal; Estrogen Receptor alpha; Female; Gene Expression; Gene Expression R | 2022 |
Effects of Soy Isoflavones, Resistant Starch and Antibiotics on Polycystic Ovary Syndrome (PCOS)-Like Features in Letrozole-Treated Rats.
Topics: Animals; Anti-Bacterial Agents; Biomarkers; Butyric Acid; Disease Models, Animal; Equol; Female; Gas | 2021 |
Ficus deltoidea ameliorates biochemical, hormonal, and histomorphometric changes in letrozole-induced polycystic ovarian syndrome rats.
Topics: Animals; Antioxidants; Blood Glucose; Corpus Luteum; Disease Models, Animal; Endometrium; Female; Fi | 2021 |
The effectiveness of resveratrol in treatment of PCOS on the basis of experimental model in rats.
Topics: Animals; Antioxidants; Disease Models, Animal; Estrous Cycle; Female; Letrozole; Ovary; Polycystic O | 2021 |
Diacerein ameliorates induced polycystic ovary in female rats via modulation of inflammasome/caspase1/IL1β and Bax/Bcl2 pathways.
Topics: Animals; Anthraquinones; Anti-Inflammatory Agents; bcl-2-Associated X Protein; Disease Models, Anima | 2022 |
Cysteine-Cysteine Motif Chemokine Receptor 5 Expression in Letrozole-Induced Polycystic Ovary Syndrome Mice.
Topics: Animals; Cysteine; Diabetes Mellitus, Type 2; Diestrus; Disease Models, Animal; Estrous Cycle; Femal | 2021 |
Letrozole Accelerates Metabolic Remodeling through Activation of Glycolysis in Cardiomyocytes: A Role beyond Hormone Regulation.
Topics: Animals; Biomarkers; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Disease Susceptibility; E | 2022 |
Topics: Animals; Butyrates; Disease Models, Animal; Female; Humans; Lactobacillus plantarum; Letrozole; Ovar | 2022 |
Network pharmacology integrated with experimental validation reveals the regulatory mechanism of action of Hehuan Yin decoction in polycystic ovary syndrome with insulin resistance.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Female; Insulin Resistance; | 2022 |
Partially purified non-polar phytocomponents from Aloe barbadensis Mill. gel restores metabolic and reproductive comorbidities in letrozole-induced polycystic ovary syndrome rodent model- an "in-vivo" study.
Topics: Aloe; Animals; Disease Models, Animal; Female; Letrozole; Mice; Plant Preparations; Polycystic Ovary | 2022 |
Comparative study of DHEA and letrozole induced polycystic ovary syndrome in post-pubertal rats.
Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Follicle Stimulating Hormone; Human | 2022 |
Diacerein ameliorates letrozole-induced polycystic ovarian syndrome in rats.
Topics: Animals; Anthraquinones; Disease Models, Animal; Female; Humans; Letrozole; Polycystic Ovary Syndrom | 2022 |
Suppression of PCSK9/NF-kB-dependent pathways by acetate ameliorates cardiac inflammation in a rat model of polycystic ovarian syndrome.
Topics: Acetates; Animals; Cardiovascular Diseases; Disease Models, Animal; Female; Humans; Inflammation; Le | 2022 |
Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model.
Topics: Animals; bcl-2-Associated X Protein; Disease Models, Animal; Female; Humans; Inflammasomes; Letrozol | 2022 |
Distinctions in PCOS Induced by Letrozole Vs Dehydroepiandrosterone With High-fat Diet in Mouse Model.
Topics: Animals; Body Weight; Dehydroepiandrosterone; Diet, High-Fat; Disease Models, Animal; Female; Humans | 2022 |
Protective efficacy of dark chocolate in letrozole-induced ovary toxicity model rats: hormonal, biochemical, and histopathological investigation.
Topics: Animals; Antioxidants; Chocolate; Disease Models, Animal; Female; Letrozole; Polycystic Ovary Syndro | 2022 |
Acetate: A therapeutic candidate against renal disorder in a rat model of polycystic ovarian syndrome.
Topics: Animals; Disease Models, Animal; Female; Insulin Resistance; Kidney Diseases; Letrozole; NF-kappa B; | 2023 |
Protective Role of Acetate Against Depressive-Like Behaviour Associated with Letrozole-Induced PCOS Rat Model: Involvement of HDAC2 and DNA Methylation.
Topics: Acetates; Animals; Disease Models, Animal; DNA; DNA Methylation; Female; Histone Deacetylase 2; Huma | 2023 |
Fenofibrate ameliorates letrozole-induced polycystic ovary in rats via modulation of PPARα and TNFα/CD95 pathway.
Topics: Animals; Anti-Mullerian Hormone; Body Weight; Disease Models, Animal; Female; Fenofibrate; Humans; I | 2022 |
The effect of Nateglinide and Octreotide on follicular morphology and free radical scavenging system in letrazole-induced rat model of PCOS.
Topics: Animals; Disease Models, Animal; Female; Follicle Stimulating Hormone; Free Radicals; Insulin-Like G | 2022 |
The effect of Nateglinide and Octreotide on follicular morphology and free radical scavenging system in letrazole-induced rat model of PCOS.
Topics: Animals; Disease Models, Animal; Female; Follicle Stimulating Hormone; Free Radicals; Insulin-Like G | 2022 |
The effect of Nateglinide and Octreotide on follicular morphology and free radical scavenging system in letrazole-induced rat model of PCOS.
Topics: Animals; Disease Models, Animal; Female; Follicle Stimulating Hormone; Free Radicals; Insulin-Like G | 2022 |
The effect of Nateglinide and Octreotide on follicular morphology and free radical scavenging system in letrazole-induced rat model of PCOS.
Topics: Animals; Disease Models, Animal; Female; Follicle Stimulating Hormone; Free Radicals; Insulin-Like G | 2022 |
Therapeutic Potential of Selenium Nanoparticles on Letrozole-Induced Polycystic Ovarian Syndrome in Female Wistar Rats.
Topics: Animals; Disease Models, Animal; Female; Humans; Interleukin-1; Letrozole; Polycystic Ovary Syndrome | 2023 |
Effects of time-restricted feeding on letrozole-induced mouse model of polycystic ovary syndrome.
Topics: Animals; Disease Models, Animal; Female; Humans; Letrozole; Luteinizing Hormone; Mice; Mice, Inbred | 2023 |
Ameliorative effect of sesame oil on experimentally induced polycystic ovary syndrome: A cross-link between XBP-1/PPAR-1, regulatory proteins for lipogenesis/steroids.
Topics: Animals; Disease Models, Animal; Female; Humans; Letrozole; Lipogenesis; Metformin; Peroxisome Proli | 2023 |
Role of diacerein on steroidogenesis and folliculogenesis related genes in ovary of letrozole-induced PCOS mice.
Topics: Animals; Disease Models, Animal; Estrogens; Female; Humans; Letrozole; Mice; Polycystic Ovary Syndro | 2023 |
Naringenin improves ovarian health by reducing the serum androgen and eliminating follicular cysts in letrozole-induced polycystic ovary syndrome in the Sprague Dawley rats.
Topics: Androgens; Animals; Disease Models, Animal; Female; Follicular Cyst; Humans; Letrozole; Metformin; P | 2023 |
Deletion of Androgen Receptors From Kisspeptin Neurons Prevents PCOS Features in a Letrozole Mouse Model.
Topics: Androgens; Animals; Disease Models, Animal; Female; Hyperandrogenism; Kisspeptins; Letrozole; Mice; | 2023 |
Comprehensive Analysis of Gut Microbiota Alteration in the Patients and Animal Models with Polycystic Ovary Syndrome.
Topics: Animals; Disease Models, Animal; Female; Gastrointestinal Microbiome; Humans; Letrozole; Polycystic | 2023 |
Modulation of GABA by sodium butyrate ameliorates hypothalamic inflammation in experimental model of PCOS.
Topics: Animals; Butyric Acid; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Humans; Letrozole; M | 2023 |
Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome.
Topics: Adult; Age Factors; Androgens; Animals; Aromatase Inhibitors; Bacterial Typing Techniques; Blood Glu | 2019 |
Hyperactive LH Pulses and Elevated Kisspeptin and NKB Gene Expression in the Arcuate Nucleus of a PCOS Mouse Model.
Topics: Animals; Arcuate Nucleus of Hypothalamus; Aromatase Inhibitors; Disease Models, Animal; Dynorphins; | 2020 |
Study of the effect of metformin on expression levels of TNF-α and IL-18 in animal models of polycystic ovary syndrome.
Topics: Animals; Carboxymethylcellulose Sodium; Disease Models, Animal; Down-Regulation; Estradiol; Estrous | 2021 |
Osteoporosis-decreased extracellular matrix stiffness impairs connexin 43-mediated gap junction intercellular communication in osteocytes.
Topics: Animals; Cell Communication; Connexin 43; Disease Models, Animal; Extracellular Matrix; Gap Junction | 2020 |
Lactic acid bacteria alleviate polycystic ovarian syndrome by regulating sex hormone related gut microbiota.
Topics: Animals; Bacteria; Bifidobacterium; Disease Models, Animal; Estrous Cycle; Fatty Acids, Volatile; Fe | 2020 |
A Rat Model of Polycystic Ovary Syndrome with Insulin Resistance Induced by Letrozole Combined with High Fat Diet.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Female; Follicle Stimulating Hormone; Insulin; Insu | 2020 |
Letrozole Rat Model Mimics Human Polycystic Ovarian Syndrome and Changes in Insulin Signal Pathways.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Estrous Cycle; Female; Insulin; Insuli | 2020 |
The effects of thylakoid-rich spinach extract and aqueous extract of caraway (Carum carvi L.) in letrozole-induced polycystic ovarian syndrome rats.
Topics: Animals; Biomarkers; Carum; Disease Models, Animal; Female; Hypoglycemic Agents; Iran; Letrozole; Me | 2020 |
GnRH protective effects against amyloid β-induced cognitive decline: A potential role of the 17β-estradiol.
Topics: Amyloid beta-Peptides; Animals; Anxiety; Cognitive Dysfunction; Disease Models, Animal; Estradiol; E | 2020 |
Beneficial phytoestrogenic effects of resveratrol on polycystic ovary syndromein rat model.
Topics: Adiponectin; Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Estradiol; Female; Le | 2021 |
The leaf aqueous extract of Myrianthus arboreus P. Beauv. (Cecropiaceae) improved letrozole-induced polycystic ovarian syndrome associated conditions and infertility in female Wistar rats.
Topics: Animals; Cameroon; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Infertility, Fe | 2020 |
Liraglutide mends cognitive impairment by averting Notch signaling pathway overexpression in a rat model of polycystic ovary syndrome.
Topics: Animals; Blood Glucose; Cognitive Dysfunction; Disease Models, Animal; Estradiol; Female; Gene Expre | 2021 |
Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model.
Topics: Animals; Aromatase Inhibitors; Caspase 3; Disease Models, Animal; Drug Evaluation, Preclinical; Fema | 2021 |
Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS.
Topics: Adiponectin; Animals; Biomarkers; Disease Models, Animal; Female; Inflammation Mediators; Letrozole; | 2021 |
Potential effect of adrenomedullin on metabolic and endocrinal dysfunctions in the experimentally induced polycystic ovary: Targeting implication of endoplasmic reticulum stress.
Topics: Adrenomedullin; Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Female; Gene Expressi | 2021 |
Beneficial effects of minocycline on the ovary of polycystic ovary syndrome mouse model: Molecular docking analysis and evaluation of TNF-α, TNFR2, TLR-4 gene expression.
Topics: Animals; Disease Models, Animal; Estradiol; Female; Humans; Letrozole; Mice; Minocycline; Molecular | 2021 |
Effects of total flavonoids from Eucommia ulmoides Oliv. leaves on polycystic ovary syndrome with insulin resistance model rats induced by letrozole combined with a high-fat diet.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Eucommiaceae; Female; Flavonoids; Gona | 2021 |
Letrozole-Induced Polycystic Ovary Syndrome Attenuates Cystathionine-β Synthase mRNA and Protein Abundance in the Ovaries of Female Sprague Dawley Rats.
Topics: Animals; Cystathionine beta-Synthase; Disease Models, Animal; Female; Letrozole; Ovary; Polycystic O | 2021 |
Inhibition of visfatin by FK866 mitigates pathogenesis of cystic ovary in letrozole-induced hyperandrogenised mice.
Topics: Acrylamides; Androgens; Animals; Blood Glucose; Cytokines; Disease Models, Animal; Female; Hyperandr | 2021 |
Effect of vitamin D on experimental model of polycystic ovary syndrome in female rats.
Topics: Animals; Caspase 3; Disease Models, Animal; Female; Letrozole; Ovary; Oxidative Stress; Polycystic O | 2021 |
Ameliorative effects of
Topics: Animals; Cuscuta; Disease Models, Animal; Female; Letrozole; Polycystic Ovary Syndrome; Rats; Rats, | 2021 |
A new clinically-relevant rat model of letrozole-induced chronic nociceptive disorders.
Topics: Animals; Aromatase Inhibitors; Body Weight; Chronic Disease; Disease Models, Animal; Female; Ganglia | 2021 |
Linum usitatissimum seeds oil down-regulates mRNA expression for the steroidogenic acute regulatory protein and Cyp11A1 genes, ameliorating letrezole-induced polycystic ovarian syndrome in a rat model.
Topics: Animals; Antioxidants; Cholesterol Side-Chain Cleavage Enzyme; Chromatography, High Pressure Liquid; | 2021 |
Uterine anomalies in cell proliferation, energy homeostasis and oxidative stress in PCOS hamsters, M. auratus: Therapeutic potentials of melatonin.
Topics: Animals; Aromatase Inhibitors; Blood Glucose; Cell Proliferation; Cricetinae; Disease Models, Animal | 2021 |
Coupling of GPR30 mediated neurogenesis and protection with astroglial Aromatase-STAT3 signaling in rat hippocampus after global cerebral ischemia.
Topics: Animals; Aromatase; Brain Ischemia; Disease Models, Animal; Estradiol; Female; Hippocampus; Letrozol | 2021 |
Ameliorative effects of fisetin in letrozole-induced rat model of polycystic ovary syndrome.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Phytogenic; Blood Glucose; Carboxymet | 2021 |
Exercise differentially affects metabolic functions and white adipose tissue in female letrozole- and dihydrotestosterone-induced mouse models of polycystic ovary syndrome.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, White; Animals; Body Composition; Body Weight; Cell Size; | 2017 |
Micturition dysfunction in four-month old ovariectomized rats: Effects of testosterone replacement.
Topics: Acetanilides; Androgens; Angiotensin II; Animals; Carbachol; Disease Models, Animal; Dose-Response R | 2017 |
Does long-term androgen deficiency lead to metabolic syndrome in middle-aged rats?
Topics: Age Factors; Andropause; Animals; Aromatase Inhibitors; Biomarkers; Blood Glucose; Blood Pressure; C | 2017 |
Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.
Topics: Adipocytes; Androgen Antagonists; Animals; Aromatase Inhibitors; Body Weight; Disease Models, Animal | 2018 |
Expression profiles of mRNA and long noncoding RNA in the ovaries of letrozole-induced polycystic ovary syndrome rat model through deep sequencing.
Topics: Animals; Disease Models, Animal; Female; Gene Expression Profiling; Gene Expression Regulation; Gene | 2018 |
Therapeutic potentials of Quercetin in management of polycystic ovarian syndrome using Letrozole induced rat model: a histological and a biochemical study.
Topics: Animals; Antioxidants; Biomarkers; Biopsy; Body Weight; Disease Management; Disease Models, Animal; | 2018 |
Aromatase inhibition by letrozole attenuates kainic acid-induced seizures but not neurotoxicity in mice.
Topics: Animals; Anticonvulsants; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Estradiol; Hippoc | 2018 |
Tetragonia tetragonioides (Pall.) Kuntze Regulates Androgen Production in a Letrozole-Induced Polycystic Ovary Syndrome Model.
Topics: Aizoaceae; Androgens; Animals; Cell Line; Cell Survival; Cyclic AMP Response Element-Binding Protein | 2018 |
Alteration at transcriptional level of cardiac renin-angiotensin system by letrozole treatment.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Female; Heart Diseases; Letrozole; Myocardiu | 2019 |
Welsh Onion Root (
Topics: Allium; Animals; Aromatase; Aromatase Inhibitors; Asia; Diet; Disease Models, Animal; Estrogens; Fem | 2018 |
Therapeutic Efficacy of Melatonin Against Polycystic Ovary Syndrome (PCOS) Induced by Letrozole in Wistar Rat.
Topics: Administration, Oral; Animals; Disease Models, Animal; Estrogens; Female; Letrozole; Melatonin; Poly | 2018 |
Effects of silymarin, cabergoline and letrozole on rat model of endometriosis.
Topics: Animals; Antioxidants; Aromatase Inhibitors; Cabergoline; Disease Models, Animal; Dopamine Agonists; | 2018 |
Shaoyao-Gancao Decoction alleviated hyperandrogenism in a letrozole-induced rat model of polycystic ovary syndrome by inhibition of NF-κB activation.
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Female; Gene Expression Regulation; Humans; | 2019 |
The Flavanone, Naringenin, Modifies Antioxidant and Steroidogenic Enzyme Activity in a Rat Model of Letrozole-Induced Polycystic Ovary Syndrome.
Topics: Animals; Antioxidants; Catalase; Disease Models, Animal; Estradiol; Female; Flavanones; Glutathione | 2019 |
Letrozole treatment of adult female mice results in a similar reproductive phenotype but distinct changes in metabolism and the gut microbiome compared to pubertal mice.
Topics: Age Factors; Animals; Aromatase Inhibitors; Disease Models, Animal; Female; Gastrointestinal Microbi | 2019 |
Exposure to a Healthy Gut Microbiome Protects Against Reproductive and Metabolic Dysregulation in a PCOS Mouse Model.
Topics: Animals; Anovulation; Aromatase Inhibitors; Disease Models, Animal; Dysbiosis; Female; Gastrointesti | 2019 |
ETA-mediated anti-TNF-α therapy ameliorates the phenotype of PCOS model induced by letrozole.
Topics: Animals; Chemokine CCL2; Disease Models, Animal; Etanercept; Female; Letrozole; Mice; NF-kappa B; Po | 2019 |
Ocimum kilimandscharicum L. restores ovarian functions in letrozole - induced Polycystic Ovary Syndrome (PCOS) in rats: Comparison with metformin.
Topics: Aged; Animals; Antioxidants; Aromatase Inhibitors; Blood Glucose; Body Weight; Chromatography, High | 2019 |
HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Topics: Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Benzamides; Disease Models, Animal; | 2013 |
Expression of anti-Müllerian hormone in letrozole rat model of polycystic ovary syndrome.
Topics: Animals; Anti-Mullerian Hormone; Aromatase Inhibitors; Disease Models, Animal; Female; Letrozole; Ni | 2014 |
Prenatal hyperandrogenic environment induced autistic-like behavior in rat offspring.
Topics: Androgens; Animals; Arginine Vasopressin; Child Development Disorders, Pervasive; Disease Models, An | 2015 |
Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis.
Topics: Animals; Anti-Inflammatory Agents; Cell Survival; Cells, Cultured; Disease Models, Animal; Disease P | 2015 |
Preclinical pharmacological evaluation of letrozole as a novel treatment for gliomas.
Topics: Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Cell Line, Tumor; Cytochrome P-450 | 2015 |
[Study on the oxidative stress in the ovaries of a rat model of polycystic ovary].
Topics: Animals; Antioxidants; Disease Models, Animal; Estrogens; Female; Follicle Stimulating Hormone; Letr | 2015 |
Dual targeting of TNF-α and free radical toxic stress as a promising strategy to manage experimental polycystic ovary.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Disease Models, Animal; Drug Therapy, C | 2016 |
Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Aromatase; Bone Neoplasms; Cell Line, Tumor; D | 2015 |
A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Blood Glucose; Cell | 2015 |
The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome.
Topics: Animals; Diet; Disease Models, Animal; Female; Gastrointestinal Microbiome; Letrozole; Mice; Nitrile | 2016 |
[Effects of compound malt pills on expressions of ERα and ERβ in ovaries of rats with letrozole-induced polycystic ovarian syndrome].
Topics: Animals; Corpus Luteum; Disease Models, Animal; Drugs, Chinese Herbal; Estrogen Receptor alpha; Estr | 2016 |
Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.
Topics: Adenosine Triphosphate; Androstadienes; Animals; Aromatase Inhibitors; Calcitonin Gene-Related Pepti | 2016 |
Effects of Exercise Intervention on Preventing Letrozole-Exposed Rats From Polycystic Ovary Syndrome.
Topics: Animals; Aromatase Inhibitors; Body Weight; Disease Models, Animal; Female; Follicle Stimulating Hor | 2017 |
Effects of cisplatin and letrozole on surgically induced endometriosis and comparison of the two medications in a rat model.
Topics: Animals; Cisplatin; Disease Models, Animal; Endometriosis; Female; Letrozole; Nitriles; Rats; Triazo | 2016 |
Kisspeptin mRNA expression is increased in the posterior hypothalamus in the rat model of polycystic ovary syndrome.
Topics: Animals; Disease Models, Animal; Female; Gene Expression Regulation; Humans; Hypothalamus, Posterior | 2017 |
Altered expression of miRNAs in the uterus from a letrozole-induced rat PCOS model.
Topics: Animals; Disease Models, Animal; Estrus; Female; Gene Expression; Humans; Letrozole; MicroRNAs; Nitr | 2017 |
Acupuncture does not ameliorate metabolic disturbances in the P450 aromatase inhibitor-induced rat model of polycystic ovary syndrome.
Topics: Acupuncture Therapy; Adipose Tissue; Animals; Aromatase; Aromatase Inhibitors; Cytochrome P-450 Enzy | 2017 |
Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats.
Topics: Animals; Antioxidants; Aromatase Inhibitors; Biomarkers; Blood Glucose; Body Weights and Measures; C | 2016 |
Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Androgen Antagonists; Animals; An | 2017 |
The role of nesfatin-1 expression in letrozole-induced polycystic ovaries in the rat.
Topics: Animals; Calcium-Binding Proteins; Disease Models, Animal; DNA-Binding Proteins; Female; Letrozole; | 2017 |
Disruption in the expression and immunolocalisation of steroid receptors and steroidogenic enzymes in letrozole-induced polycystic ovaries in rat.
Topics: 3-Hydroxysteroid Dehydrogenases; Animals; Aromatase; Blotting, Western; Diestrus; Disease Models, An | 2009 |
Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis.
Topics: Anastrozole; Animals; Apoptosis; Aromatase; Aromatase Inhibitors; Ascitic Fluid; Cell Proliferation; | 2010 |
Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; | 2010 |
The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model.
Topics: Animals; Aromatase Inhibitors; Disease Models, Animal; Endometriosis; Female; Hypoglycemic Agents; L | 2010 |
Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model.
Topics: Animals; Antibodies, Monoclonal; Aromatase Inhibitors; Ascitic Fluid; Disease Models, Animal; Endome | 2011 |
Inhibition of oestrogen biosynthesis induces mild anxiety in C57BL/6J ovariectomized female mice.
Topics: Animals; Anxiety; Aromatase Inhibitors; Depression; Disease Models, Animal; Estradiol; Female; Hippo | 2011 |
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase; | 2012 |
Combination of acupuncture and chinese medicinal herbs in treating model rats with polycystic ovary syndrome.
Topics: Acupuncture Therapy; Administration, Oral; Animals; Benzofurans; Chromatography, High Pressure Liqui | 2011 |
Successful combination: existing drugs boost cancer vaccine responses.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines | 2012 |
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Nucle | 2012 |
Aromatase inhibitor treatment limits progression of peritoneal endometriosis in baboons.
Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Disease Progression; Endometriosis | 2013 |
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Estr | 2002 |
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Cell | 2003 |
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Dis | 2004 |
Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Topics: Animals; Antineoplastic Agents; Aromatase; Body Composition; Breast Neoplasms; Cell Division; Cell L | 2004 |
Aromatase inhibitors--a triumph of translational oncology.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adju | 2005 |
The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model.
Topics: Androstenedione; Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Fe | 2007 |
A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome.
Topics: Adipocytes; Androgens; Animals; Aromatase Inhibitors; Body Composition; Body Weight; Dihydrotestoste | 2007 |
Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer.
Topics: Animals; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Cyclin D; Cyclin | 2008 |
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 1999 |